MetaVia's Groundbreaking Research Presentation
MetaVia Inc. (NASDAQ: MTVA), a clinical-stage biotechnology company dedicated to transforming cardiometabolic diseases, is generating excitement as it prepares to present significant research on Vanoglipel (DA-1241). This innovative G-Protein-Coupled Receptor 119 (GPR119) agonist has caught the attention of the scientific community, with an abstract accepted for a poster presentation at the prestigious American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025.
Details of the Poster Presentation
The poster presentation is scheduled for November 10, 2025, during the Monday Poster Presenters Hall Hour. Here are the essential details:
- Title: Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver: A 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients
- Presenting Author: Rohit Loomba, M.D., MHSc, renowned expert in Gastroenterology and Hepatology
- Poster Number: 4012
- Session: Monday Poster Presenters Hall Hour
- Poster Time: 1:00-2:00 pm ET
- Poster Location: Convention Center: Hall DE (Posters & Exhibits), Level 2
After the presentation, interested individuals can find a copy of the poster in the Posters section of the MetaVia website.
About Vanoglipel (DA-1241)
Vanoglipel (DA-1241) stands at the forefront of therapeutic innovation, acting as a GPR119 agonist designed to address both Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes (T2D). By stimulating GPR119 in the gut, this treatment enhances the release of vital gut peptides such as GLP-1, GIP, and PYY. These peptides are essential for glucose regulation, lipid metabolism, and promoting weight loss.
The preclinical studies demonstrate DA-1241's ability to significantly improve conditions associated with glucose and lipid profiles, especially in the context of liver inflammation. Results gathered from various models indicate that this compound could remarkably reduce hepatic steatosis, inflammation, and fibrosis, while also enhancing glucose control.
In early Phase trials, DA-1241 proved its safety and tolerability in healthy subjects and those diagnosed with T2DM. Impressively, it also exhibited direct hepatic actions alongside its glucose-lowering capabilities during a Phase 2a clinical study.
About MetaVia Inc.
MetaVia Inc. is committed to pioneering solutions in the realm of cardiometabolic diseases. In addition to developing Vanoglipel (DA-1241), the company is progressing with another promising candidate, DA-1726, targeted at obesity treatment. DA-1726 is an innovative oxyntomodulin analogue, acting as a dual agonist for GLP1R and GCGR. This dual action is geared towards reducing food intake while boosting energy expenditure, showing great promise in weight loss and significant benefits in glucose control.
Current research has showcased DA-1726's potential as a frontrunner in aiding weight loss and managing metabolic conditions, according to data from its Phase 1 multiple ascending dose trial. Both DA-1241 and DA-1726 exemplify MetaVia's dedication to improving patient outcomes through advanced science and innovation.
For more detailed information, individuals can visit the official MetaVia website.
Frequently Asked Questions
What is the significance of MetaVia's upcoming poster presentation?
The presentation will showcase pivotal research data on Vanoglipel (DA-1241) and its potential benefits in treating liver diseases and metabolic disorders.
Who is the presenting author at the AASLD Liver Meeting?
The poster will be presented by Dr. Rohit Loomba, an expert in the field of Gastroenterology and Hepatology.
When is the poster presentation scheduled?
The poster presentation is set for November 10, 2025.
What is Vanoglipel (DA-1241) and how does it work?
Vanoglipel (DA-1241) is a GPR119 agonist that promotes the release of gut peptides beneficial for glucose and lipid metabolism, aiding in the treatment of MASH and T2D.
What other products is MetaVia developing?
MetaVia is also working on DA-1726, which is aimed at combating obesity by acting as a GLP1R and GCGR dual agonist.
